Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
Atherosclerosis burden across subtypes of steatotic liver disease: a European cohort analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bauer Johannes, Gensluckner Sophie, Eberhardt Julian, Akhgar Alexander, Datz Christian, Iglseder Bernhard, Langthaler Patrick, Trinka Eugen, Ausserwinkler Mathias, Semmler Georg, Paulweber Bernhard, Aigner Elmar, Wernly Bernhard
Аннотация
BACKGROUND AND AIM: Steatotic liver disease (SLD) affects over 30% of adults and is classified into metabolic dysfunction-associated (MASLD), alcohol-related (ALD), and metabolic dysfunction and alcohol-associated (MetALD) subtypes. Cardiovascular disease is the leading cause of death in SLD, yet the differential atherosclerotic risk across subtypes remains uncertain.
METHODS AND RESULTS: We conducted a cross-sectional analysis of 7820 participants from the population-based Paracelsus 10,000 cohort. SLD was defined by the Fatty Liver Index according to international consensus criteria. Atherosclerosis was assessed by carotid ultrasonography (n = 7820), coronary artery calcium (CAC) scoring by computed tomography (n = 1434), and polygenic risk scores (PGS, n = 1652). Primary outcomes were carotid plaque presence and CAC burden (Agatston score). Multivariable logistic regression adjusted for age, sex, and SCORE2 cardiovascular risk. We identified 5448 controls (69.7%), 2098 MASLD (26.8%), 201 ALD (2.6%), and 73 MetALD (0.9%). Carotid plaque prevalence increased stepwise: 30% in controls, 47% in MASLD, 53% in MetALD, and 62% in ALD (p<0.001). High-risk CAC (Agatston >300) was present in 4% of controls, 7% of MASLD, and 18% of both MetALD and ALD (p<0.001). Unadjusted odds ratios for plaque were 2.10 (95% CI, 1.89-2.33) for MASLD, 2.69 (1.69-4.28) for MetALD, and 3.86 (2.89-5.16) for ALD. After SCORE2 adjustment, associations attenuated and lost statistical significance. CAD-PGS differed modestly across subtypes (p=0.019) and inclusion further attenuated associations.
CONCLUSIONS: All SLD subtypes were associated with increased atherosclerotic burden, with ALD showing the highest risk. Associations were attenuated after adjustment for established cardiovascular risk factors, indicating shared cardiometabolic rather than liver-specific pathways.
METHODS AND RESULTS: We conducted a cross-sectional analysis of 7820 participants from the population-based Paracelsus 10,000 cohort. SLD was defined by the Fatty Liver Index according to international consensus criteria. Atherosclerosis was assessed by carotid ultrasonography (n = 7820), coronary artery calcium (CAC) scoring by computed tomography (n = 1434), and polygenic risk scores (PGS, n = 1652). Primary outcomes were carotid plaque presence and CAC burden (Agatston score). Multivariable logistic regression adjusted for age, sex, and SCORE2 cardiovascular risk. We identified 5448 controls (69.7%), 2098 MASLD (26.8%), 201 ALD (2.6%), and 73 MetALD (0.9%). Carotid plaque prevalence increased stepwise: 30% in controls, 47% in MASLD, 53% in MetALD, and 62% in ALD (p<0.001). High-risk CAC (Agatston >300) was present in 4% of controls, 7% of MASLD, and 18% of both MetALD and ALD (p<0.001). Unadjusted odds ratios for plaque were 2.10 (95% CI, 1.89-2.33) for MASLD, 2.69 (1.69-4.28) for MetALD, and 3.86 (2.89-5.16) for ALD. After SCORE2 adjustment, associations attenuated and lost statistical significance. CAD-PGS differed modestly across subtypes (p=0.019) and inclusion further attenuated associations.
CONCLUSIONS: All SLD subtypes were associated with increased atherosclerotic burden, with ALD showing the highest risk. Associations were attenuated after adjustment for established cardiovascular risk factors, indicating shared cardiometabolic rather than liver-specific pathways.
Предметные рубрики MeSH
HumansCross-Sectional StudiesFemaleCarotid Artery DiseasesRisk FactorsMaleEuropePrevalencePlaque, AtheroscleroticMiddle AgedCoronary Artery DiseaseUltrasonography, Carotid ArteriesVascular CalcificationAgedFatty Liver, AlcoholicFatty LiverRisk AssessmentGenetic Risk ScoreComputed Tomography AngiographyCoronary AngiographyAdultNon-alcoholic Fatty Liver Disease